Cardinal Health Inc (CAH)
$118.10 $0.88 (0.75%) 10:16 PM 12/14/24
NYSE | $USD | Medical DistributionStock Data
-
Market Cap
$28.58B -
Day's Range
$117.07 - $118.91 -
Volume
1,904,226 -
52 Week Low / High
$92.74 - $126.23 -
PE Ratio
22.71x -
PEG Ratio
1.00 -
Dividend Frequency
quarterly
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 4
- Strong Buy
- 1
- Buy
- 10
- Hold
- 1
- Sell
- 1
- Strong Sell
- $98.58
- Target Price
Company News
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Q3 2024 T2 Biosystems Inc Earnings Call — Oct 11th, 2024
Participants Philip Taylor; Investor Relations; T2 Biosystems Inc John Sperzel; Chairman of the Board, President, Chief Executive Officer; T2 Biosystems Inc Eduardo Martinez; Analyst; H.C. Wainwright & Co., LLC Presentation Operator Good day, everyone, and welcome to the T2 Biosystem...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Are Investors Undervaluing Cardinal Health (CAH) Right Now? — Oct 11th, 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Q3 2024 T2 Biosystems Inc Earnings Call — Oct 11th, 2024
Participants Philip Taylor; Investor Relations; T2 Biosystems Inc John Sperzel; Chairman of the Board, President, Chief Executive Officer; T2 Biosystems Inc Eduardo Martinez; Analyst; H.C. Wainwright & Co., LLC Presentation Operator Good day, everyone, and welcome to the T2 Biosystem...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Q3 2024 T2 Biosystems Inc Earnings Call — Oct 11th, 2024
Participants Philip Taylor; Investor Relations; T2 Biosystems Inc John Sperzel; Chairman of the Board, President, Chief Executive Officer; T2 Biosystems Inc Eduardo Martinez; Analyst; H.C. Wainwright & Co., LLC Presentation Operator Good day, everyone, and welcome to the T2 Biosystem...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Are Investors Undervaluing Cardinal Health (CAH) Right Now? — Oct 11th, 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? — Oct 11th, 2024
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Aveanna Healthcare (AVAH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical pe...
-
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? — Oct 11th, 2024
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Aveanna Healthcare (AVAH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical pe...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Are Investors Undervaluing Cardinal Health (CAH) Right Now? — Oct 11th, 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Here's Why Cardinal Health (CAH) is a Strong Momentum Stock — Oct 16th, 2024
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to us...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Q3 2024 T2 Biosystems Inc Earnings Call — Oct 11th, 2024
Participants Philip Taylor; Investor Relations; T2 Biosystems Inc John Sperzel; Chairman of the Board, President, Chief Executive Officer; T2 Biosystems Inc Eduardo Martinez; Analyst; H.C. Wainwright & Co., LLC Presentation Operator Good day, everyone, and welcome to the T2 Biosystem...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Cardinal Health (CAH) Stock Dips While Market Gains: Key Facts — Oct 14th, 2024
Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq...
-
Cardinal Health Revenue Jumps on Wider Use of Obesity Drugs — Nov 1st, 2024
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third...
-
Are Investors Undervaluing Cardinal Health (CAH) Right Now? — Oct 11th, 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing...
-
Here's Why Cardinal Health (CAH) is a Strong Value Stock — Oct 17th, 2024
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is ...
-
Q3 2024 T2 Biosystems Inc Earnings Call — Oct 11th, 2024
Participants Philip Taylor; Investor Relations; T2 Biosystems Inc John Sperzel; Chairman of the Board, President, Chief Executive Officer; T2 Biosystems Inc Eduardo Martinez; Analyst; H.C. Wainwright & Co., LLC Presentation Operator Good day, everyone, and welcome to the T2 Biosystem...
Portfolio
Comprised of 1 portfolios